Living donor robotic-assisted kidney transplant compared to traditional living donor open kidney transplant. Where do we stand now? A systematic review and meta-analysis

IF 3.6 2区 医学 Q2 IMMUNOLOGY
Mario A. O'Connor-Cordova , Alan G. Ortega-Macias , Juan P. Sancen-Herrera , Francisco Altamirano-Lamarque , Alexis Vargas del Toro , Andres Inzunza Martin del Campo , Pia Canal-Zarate , Bharat Kumar Peddinani , Fernando Gonzalez-Zorrilla , Mario O'Connor Juarez
{"title":"Living donor robotic-assisted kidney transplant compared to traditional living donor open kidney transplant. Where do we stand now? A systematic review and meta-analysis","authors":"Mario A. O'Connor-Cordova ,&nbsp;Alan G. Ortega-Macias ,&nbsp;Juan P. Sancen-Herrera ,&nbsp;Francisco Altamirano-Lamarque ,&nbsp;Alexis Vargas del Toro ,&nbsp;Andres Inzunza Martin del Campo ,&nbsp;Pia Canal-Zarate ,&nbsp;Bharat Kumar Peddinani ,&nbsp;Fernando Gonzalez-Zorrilla ,&nbsp;Mario O'Connor Juarez","doi":"10.1016/j.trre.2023.100789","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Renal transplant<span> is the standard of care for patients with end-stage renal disease (ESRD). Robotic-assisted kidney transplant (RAKT) has emerged as a safe minimally invasive approach with a lower complication rate than open kidney transplant (OKT). Concerns regarding ischemia times and graft function are still a matter of debate.</span></p></div><div><h3>Methods</h3><p>Following PRISMA guidelines and PROSPERO registration CRD42023413774, a systematic review was performed in March 2023 on RAKT compared to OKT. Primary outcomes of interest were surgical times, ischemia times, blood loss, complication rates, and graft function. Data were analyzed using R version 4.2.2.</p></div><div><h3>Results</h3><p><span>A total of nine studies comparing living donor RAKT to living donor OKT were included, totaling 1477 patients, out of which 508 underwent RAKT and 969 OKT. RAKT cases were highly selected as depicted in the manuscript. Cumulative analysis showed significantly longer total ischemic time<span><span> (MD = 16.51; 95% CI = [9.86–23.16]) and rewarming ischemia time (MD = 11.24; 95% CI = [−0.46–22.01]) in RAKT group. No differences were found in total procedure time and time to complete anastomoses. Blood loss and transfusion rate were lower in RAKT group (MD = −53.68; 95% CI = [−89.78; −17.58]) and (RR = 0.29; 95% CI = [0.14; 0.57]), respectively. The meta-analysis revealed a lower rate of </span>surgical site infection<span><span> (SSI) (RR = 0.31; 95% CI = [0.19–0.52]) and symptomatic lymphocele (RR = 0.16; 95% CI = [0.06–0.43]) in RAKT. No difference in </span>ileus rate was found. Pain scores were significantly lower in the RAKT group (MD = -1.14; 95% CI = [−1.59 - -0.69]; </span></span></span><em>p</em><span> ≤0.01). No difference in length of stay and hospital readmission were evidenced. Delayed graft function<span> (DGF) and acute rejection rates were not different between interventions groups (RR =1.23; 95% CI = [0.40–3.74]) and (RR =0.96; 95% CI = [0.55–1.70]), respectively. No difference between groups in early graft outcomes are evident.</span></span></p></div><div><h3>Conclusions</h3><p>Our analysis suggests that RAKT is a minimally invasive, safe, and feasible procedure. It is associated with a lower complication rate and similar intraoperative, perioperative, and postoperative outcomes. Further quality studies are needed to confirm these findings.</p></div>","PeriodicalId":48973,"journal":{"name":"Transplantation Reviews","volume":"37 4","pages":"Article 100789"},"PeriodicalIF":3.6000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0955470X23000435","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Renal transplant is the standard of care for patients with end-stage renal disease (ESRD). Robotic-assisted kidney transplant (RAKT) has emerged as a safe minimally invasive approach with a lower complication rate than open kidney transplant (OKT). Concerns regarding ischemia times and graft function are still a matter of debate.

Methods

Following PRISMA guidelines and PROSPERO registration CRD42023413774, a systematic review was performed in March 2023 on RAKT compared to OKT. Primary outcomes of interest were surgical times, ischemia times, blood loss, complication rates, and graft function. Data were analyzed using R version 4.2.2.

Results

A total of nine studies comparing living donor RAKT to living donor OKT were included, totaling 1477 patients, out of which 508 underwent RAKT and 969 OKT. RAKT cases were highly selected as depicted in the manuscript. Cumulative analysis showed significantly longer total ischemic time (MD = 16.51; 95% CI = [9.86–23.16]) and rewarming ischemia time (MD = 11.24; 95% CI = [−0.46–22.01]) in RAKT group. No differences were found in total procedure time and time to complete anastomoses. Blood loss and transfusion rate were lower in RAKT group (MD = −53.68; 95% CI = [−89.78; −17.58]) and (RR = 0.29; 95% CI = [0.14; 0.57]), respectively. The meta-analysis revealed a lower rate of surgical site infection (SSI) (RR = 0.31; 95% CI = [0.19–0.52]) and symptomatic lymphocele (RR = 0.16; 95% CI = [0.06–0.43]) in RAKT. No difference in ileus rate was found. Pain scores were significantly lower in the RAKT group (MD = -1.14; 95% CI = [−1.59 - -0.69]; p ≤0.01). No difference in length of stay and hospital readmission were evidenced. Delayed graft function (DGF) and acute rejection rates were not different between interventions groups (RR =1.23; 95% CI = [0.40–3.74]) and (RR =0.96; 95% CI = [0.55–1.70]), respectively. No difference between groups in early graft outcomes are evident.

Conclusions

Our analysis suggests that RAKT is a minimally invasive, safe, and feasible procedure. It is associated with a lower complication rate and similar intraoperative, perioperative, and postoperative outcomes. Further quality studies are needed to confirm these findings.

活体供体机器人辅助肾移植与传统活体供体开放肾移植的比较。我们现在的处境如何?系统回顾和荟萃分析
背景肾移植是终末期肾病(ESRD)患者的标准护理。机器人辅助肾移植(RAKT)已成为一种安全的微创方法,其并发症发生率低于开放式肾移植(OKT)。对缺血时间和移植物功能的关注仍然是一个有争议的问题。方法根据PRISMA指南和PROSPERO注册号CRD42023413774,于2023年3月对RAKT与OKT进行了系统回顾。主要关注的结果是手术时间、缺血时间、失血、并发症发生率和移植物功能。使用R版本4.2.2.对数据进行分析。结果共纳入9项比较活体供体RAKT和活体供体OKT的研究,共1477名患者,其中508名患者接受了RAKT,969名患者接受OKT。如手稿所示,RAKT病例被高度选择。累积分析显示,RAKT组的总缺血时间(MD=16.51;95%CI=[9.86–23.16])和复温缺血时间(MD=11.24;95%CI=[-0.46–22.01])显著延长。在总手术时间和完成吻合的时间上没有发现差异。RAKT组的失血量和输血率分别较低(MD=−53.68;95%CI=[-89.78;−17.58])和(RR=0.29;95%CI=[0.14;0.57])。荟萃分析显示,RAKT的手术部位感染(SSI)(RR=0.31;95%CI=[0.19-0.52])和症状性淋巴囊肿(RR=0.16;95%CI=0.06-0.43])的发生率较低。肠梗阻发生率无差异。RAKT组的疼痛评分明显较低(MD=-1.14;95%CI=[−1.59--0.69];p≤0.01)。住院时间和再次入院没有差异。干预组之间的延迟移植物功能(DGF)和急性排斥反应发生率没有差异(RR=1.23;95%CI=[0.40-3.74])和(RR=0.96;95%CI=[0.55-1.70])。两组早期移植物结果无明显差异。结论RAKT是一种微创、安全、可行的手术方法。它与较低的并发症发生率和相似的术中、围手术期和术后结果有关。需要进一步的质量研究来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Transplantation Reviews
Transplantation Reviews IMMUNOLOGY-TRANSPLANTATION
CiteScore
7.50
自引率
2.50%
发文量
40
审稿时长
29 days
期刊介绍: Transplantation Reviews contains state-of-the-art review articles on both clinical and experimental transplantation. The journal features invited articles by authorities in immunology, transplantation medicine and surgery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信